The prognostic utility of haptoglobin genotypes in squamous cell carcinoma of the head and neck

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 10, 2009, Pages 1277-1283

  Lee, Ching Chih ^a,b,c   Lee, Moon Sing ^b,c   Ho, Hsu Chueh ^b,c   Hung, Shih Kai ^b,c   Tung, Ya Ting ^b   Chou, Pesus ^a   Su, Yu Chieh ^b,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Genotype; Haptoglobin; Head and neck squamous cell carcinoma; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; HAPTOGLOBIN;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISTANT METASTASIS; EVENT FREE SURVIVAL; FEMALE; GENOTYPE; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; MULTIMODALITY CANCER THERAPY; OROPHARYNX; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK FACTOR; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HAPTOGLOBINS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 70349820380     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.275     Document Type: Article

References (25)

1. Cancer Registry Annual Report, Republic of China, 2001. Department of Health, The Executive Yuan, 2004.
2. Marinkovic S, Baumann H. Structure, hormonal regulation, and identification of the interleukin-6- and dexamethasone- responsive element of the rat haptoglobin gene. Mol Cell Biol 1990;10:1573-1583
3. Carter K, Worwood M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol 2007;29:92-110.
4. Delanghe JR, Langlois MR, Boelaert JR, Van Acker J, Van Wanzeele F, van der Groen G, et al. Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS 1998;12:1027-1032
5. Van Vlierberghe H, Langlois M, Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta 2004;345:35-42.
6. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589-1600
7. Tseng CF, Lin CC, Huang HY, Lin HC, Mao SJ. Antioxidant role of human haptoglobin. Proteomics 2004;4: 2221-2228
8. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993;91:977-985
9. de Kleijn DPV, Smeets MB, Kemmeren PP, Lim SK, Van Middelaar BJ, Velema E, et al. Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring. FASEB J 2002;16:1123-1125
10. Wolf GT, Wolfe RA. Circulating immune-complexes in patients with nasopharyngeal carcinoma. Laryngoscope 1990;100:302-308
11. Gallo O, Gori AM, Attanasio M, Martini F, Giusti B, Brunelli T, et al. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Otorhinolaryngol 1995; 252:159-162
12. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 2002; 48:1377-1382
13. Koch W, Latz W, Eichinger M, Gschwender C, Teige B, Schoming A, et al. Haptoglobin gene subtyping by restriction enzyme analysis. Clin Chem 2003;49:1937-1940
14. Koda Y, Soejima M, Yoshioka N, Kimura H. The haptoglobin- gene deletion responsible for anhaptoglobinemia. Am J Hum Genet 1998;62:245-252
15. Koda Y, Watanabe Y, Soejima M, Shimada E, Nishumura M, Morishita K, et al. Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions. Blood 2000;95:1138-1143
16. Lee CC, Lin HY, Hung SK, Li DK, Ho HC, Lee MS, et al. Haptoglobin genotypes in nasopharyngeal carcinoma. Int J Biol Marker 2009;24:32-37
17. Gast MC, van Tinteren H, Bontenbal M, van Hoesel RQ, Nooij MA, Rodenhuis S, et al. Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer 2008;8:389.
18. Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin. A biologic fenton reagent. J Biol Chem 1984;259:14354-14356
19. Gutteridge JM. The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim Biophys Acta 1987;917:219-223
20. Lim YK, Jenner A, Ali AB, Wang T, Hsu SI, Chong SM, et al. Haptoglobin reduces renal oxidative DNA and tissue damage during phenylhydrazine-induced hemolysis. Kidney Int 2000;58:1033-1044
21. Thomas L. Haptoglobin/Hämopexin. In: Thomas L, editor. Labor und Diagnose, 4th ed. Marburg: Medizinische Verlagsgesellschaft 1992:813-820
22. Na N, Delanghe JR, Taes YE, Torck M, Baeyens WR, Ouyang J. Serum vitamin C concentration is influenced by haptoglobin polymorphism and iron status in Chinese. Clin Chim Acta 2003;365:319-324
23. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996;5:19-36.
24. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Rad Biol Med 1996;20:553-566
25. Kuhajda FP, Katumuluwa AI, Pasternack GR. Expression of haptoglobin-related protein and its potential role as a tumor antigen. Proc Natl Acad Sci USA 1989;86:1188-1192